Interferon-Gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma - Related Studies

Interferon-Gamma or Aldesleukin and Vaccine Therapy in Treating Patients With Multiple Myeloma

This study is ongoing, but not recruiting participants.

Study NCT00616720. Last updated on November 16, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Additional conditions recognized in this trial
		Multiple Myeloma
		Neoplasms, Plasma Cell

2	More general conditions related to this trial
		Blood Protein Disorders
		Cardiovascular Diseases
		Hematologic Diseases
		Hemorrhagic Disorders
		Hemostatic Disorders
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type
		Paraproteinemias
		Vascular Diseases

3	Interventions listed in this trial
		aldesleukin
		recombinant interferon gamma
		flow cytometry
		laboratory biomarker analysis
		polymerase chain reaction

4	Additional drug interventions recognized in this trial
		Interferon Alfa-2b
		Interferon Type II
		Interferon-gamma, Recombinant
		Interferons

5	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Anti-HIV Agents
		Anti-Infective Agents
		Anti-Retroviral Agents
		Antineoplastic Agents
		Antiviral Agents
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Therapeutic Uses

6	Sponsors listed in this trial
		Mayo Clinic